Market Cap
$5.0B
GRFS
Grifols SA
$7.31 ▲ +0.14%
Prev close $7.30Market cap$5.0B
12-mo target$10.87 (+48.6%)
21 New Institutional Positions17 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on GRFS right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Inst. Holders
50 funds
Inst. Value
$721.8M
Inst. Activity
21 buys / 17 sells
Social Sentiment
50° Neutral
SEC Reports
2
Press Releases
3
Price chart 30d -6.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 clinical_trial_readout
Aug 10, 2026 Press Results Pending: Alpha-1 MP (Phase 3) — Completed 86d ago
Trial: Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in
Grifols announced completion of the clinical portion (last patient, last visit) of its Phase 3 SPARTA trial evaluating P
Impact 4/10
Grifols announced the resignation of independent director Iñigo Sánchez-Asiaín Mardones (Audit Committee Chair, Strategy
6-K — Impact 2/10
Grifols announced first patient dosing in two Phase 3 trials (SIGMA and XPERT) seeking U.S. label expansion for its immu
Impact 4/10
Jun 30, 2026 Inst.
BANK OF AMERICA CORP — ADD
6,550,337 shares ($46.4M)
Jun 30, 2026 Inst.
Jun 18, 2026 SEC BlackRock, Inc. — ADD
2,029,612 shares ($14.4M)
Grifols SA reported the results of its Ordinary General Shareholders' Meeting held on June 18, 2026. Shareholders approv
6-K — Impact 3/10
Analyst ratings buy % -4.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Dec 8, 2025 | JP Morgan | MAINTAIN | Neutral | 55% |
| Jun 17, 2025 | JP Morgan | MAINTAIN | Neutral | 55% |
| Mar 12, 2024 | Deutsche Bank | DOWNGRADE | Sell | 58% |
| Dec 5, 2023 | JP Morgan | MAINTAIN | Neutral | 55% |
| Nov 5, 2021 | Deutsche Bank | DOWNGRADE | Hold | 58% |
| Mar 23, 2021 | Credit Suisse | UPGRADE | Outperform | — |
| Mar 11, 2021 | HSBC | UPGRADE | Buy | 55% |
| Oct 28, 2019 | Santander | UPGRADE | Buy | — |
| Jun 27, 2019 | JP Morgan | UPGRADE | Overweight | 55% |
| Feb 8, 2019 | Berenberg | DOWNGRADE | Hold | 31% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 9 | 5 | 2 | 0 | 67% | |
| Aug 1, 2026 | 5 | 9 | 5 | 2 | 0 | 67% | |
| Jul 1, 2026 | 5 | 9 | 5 | 2 | 0 | 67% | |
| Jun 1, 2026 | 5 | 9 | 5 | 2 | 0 | 67% | |
| May 1, 2026 | 5 | 9 | 5 | 2 | 0 | 67% | |
| Apr 1, 2026 | 5 | 9 | 5 | 2 | 0 | 67% | |
| Mar 1, 2026 | 5 | 10 | 4 | 2 | 0 | 71% | |
| Feb 1, 2026 | 5 | 10 | 4 | 2 | 0 | 71% |
Price targets
Where 2 covering analysts think GRFS trades over the next 12 months.
$10.87 +48.6% upside Strong Buy
Current$7.31 Low$10.00 Median$10.87 High$11.73 2 analysts
$10.00$11.73
Analyst rating None as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
2 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 2 neutral · avg impact 2.5/10.Plus 3 press releases.
NEUTRAL6-K2/10
Grifols announced the resignation of independent director Iñigo Sánchez-Asiaín Mardones (Audit Commi
Jul 30, 2026
NEUTRAL6-K3/10
Grifols SA reported the results of its Ordinary General Shareholders' Meeting held on June 18, 2026.
Jun 18, 2026
NEUTRAL4/10
Grifols announced completion of the clinical portion (last patient, last visit) of its Phase 3 SPART
Aug 10, 2026
NEUTRAL4/10
Grifols announced first patient dosing in two Phase 3 trials (SIGMA and XPERT) seeking U.S. label ex
Jul 16, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
Clinical Trial
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)
Phase Phase 3 — COMPLETED
Oct 1, 2026
clinical_trial_readout
Results Pending: Alpha-1 MP (Phase 3) — Completed 86d ago
Trial: Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 An
Aug 10, 2026
fda
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
BARCELONA, Spain, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of pla
Jul 16, 2026
fda
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of pla
May 20, 2026
clinical_trial_readout
T-90d Trial Readout: Alpha-1 MP (Phase 3)
Trial: Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 An
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.30 | $0.30–$0.30 | — | +6.5% | 1↑ 0↓ | $2.0B | 1 |
| Next Q | $0.39 | $0.39–$0.39 | — | -13.1% | 0↑ 1↓ | $2.1B | 1 |
| Current FY | $1.16 | $1.08–$1.24 | 34.6% | +4.4% | 0↑ 1↓ | $7.7B | 2 |
| Next FY | $1.44 | $1.34–$1.54 | 24.3% | +0.9% | 1↑ 1↓ | $8.1B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.304 | — |
| 7d ago | $0.285 | +0.019 |
| 30d ago | $0.285 | +0.019 |
| 60d ago | $0.294 | +0.010 |
| 90d ago | $0.294 | +0.010 |
Institutional ownership
Which big funds own GRFS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $721.8M total value (101,848,610 shares) as of 2026-Q2. Top holders: BRANDES, Capital, BANK. Net buying activity: 21 institutions added/increased vs 17 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BRANDES INVESTMENT PARTNERS, LP | 37,816,285 | $267.7M | 37.1% | — |
| Capital World Investors | 22,911,656 | $162.2M | 22.5% | — |
| BANK OF AMERICA CORP /DE/ | 6,550,337 | $46.4M | 6.4% | ADD +51.4% |
| MILLENNIUM MANAGEMENT LLC | 4,369,934 | $30.9M | 4.3% | TRIM -29.7% |
| Jupiter Topco LLC | 2,958,981 | $20.9M | 2.9% | — |
| MORGAN STANLEY | 2,661,180 | $18.8M | 2.6% | — |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2,646,607 | $18.7M | 2.6% | — |
| NEW YORK STATE COMMON RETIREMENT FUND | 2,452,728 | $17.4M | 2.4% | — |
| BlackRock, Inc. | 2,029,612 | $14.4M | 2.0% | ADD +34.3% |
| JPMORGAN CHASE & CO | 1,927,976 | $14.1M | 2.0% | TRIM -28.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 4,327,413 | 6,550,337 | +51.4% | $46.4M |
| BlackRock, Inc. | ADD | 1,511,621 | 2,029,612 | +34.3% | $14.4M |
| JPMORGAN CHASE & CO | TRIM | 2,701,572 | 1,927,976 | -28.6% | $14.1M |
| NORGES BANK | NEW | — | 1,840,000 | — | $13.0M |
| UBS Group AG | TRIM | 3,156,653 | 1,828,586 | -42.1% | $12.9M |
| BARCLAYS PLC | TRIM | 2,104,594 | 808,187 | -61.6% | $5.7M |
| Hudson Bay Capital Management LP | ADD | 287,874 | 435,361 | +51.2% | $3.1M |
| Qube Research & Technologies Ltd | ADD | 220,377 | 406,087 | +84.3% | $2.9M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 172,722 | 261,581 | +51.4% | $1.9M |
| BANK OF MONTREAL /CAN/ | NEAR_EXIT | 2,506,278 | 227,910 | -90.9% | $1.6M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for GRFS.
Shares short
3,414,455
Settlement Sep 15, 2026
Change vs prior
-0.1%
Semi-monthly cycle
Days to cover
8.8
At avg daily volume
Of shares outstanding
≈0.5%
Estimate — not % of float
All GRFS filing & press-release reports (5)
- PRESS-RELEASE reportAug 10, 2026
- 6-K reportJul 30, 2026
- PRESS-RELEASE reportJul 16, 2026
- 6-K reportJun 18, 2026
- PRESS-RELEASE reportMar 17, 2026